The nightly ledger

Stock catalysts from the latest SEC filings

Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.

By event type: Acquisitions · Major contracts

Seven-day window, 1 week back · Material filings: 447 · All filings: 661

Material

Friday 13 Nov5 filings read · 5 material

  • 8-KFiled 13 Nov 2026Biotech

    Jade Biosciences, Inc.JBIO

    8-K · Item 2.02 — Results of operations

    Jade Biosciences advanced multiple clinical programs ahead of schedule. JADE101 Phase 3 trial (EVERGREEN) initiating Q4 2026; JADE301 Phase 1 expected Q4 2026. Cash runway extended to Q4 2028 ($475.7M). Multiple clinical catalysts expected in 2027.

    Gap Very high · 79 → Very high · 83

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 13 Nov 2026All industries

    SBC Medical Group Holdings IncSBC

    8-K · Item 2.02 — Results of operations

    Q3 2026: Revenue +35% YoY to $59M, operating income +66% to $26M, net income +22% to $16M. Adjusted EBITDA +66% to $28M with 47% margin. Clinic network expanded 36 locations to 293; patient visits +9% YoY.

    No notable change in AIR's read.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 13 Nov 2026All industries

    Realloys Inc.ALOY

    8-K · Item 2.02 — Results of operations

    REalloys executed non-binding term sheet with U.S. Army for heavy rare earth processing facility at Tooele Army Depot; advanced metallization and processing programs targeting North American rare earth metal production beginning 2027; maintains $116.2M cash, virtually debt-free.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 13 Nov 2026All industries

    Contango Silver & Gold Inc.CTGO

    8-K · Item 2.02 — Results of operations

    Q3-2026 results show significant operational headwinds: gold production down 56% YoY due to mine pit transition and mill processing delays; net loss of $23.0M vs. prior-year loss of $5.4M; cash position declined to $56.6M from $64.8M year-end.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 13 Nov 2026Biotech

    Inhibrx Biosciences, Inc.INBX

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show $38.7M net loss (vs. $35.3M prior year), increased debt to $275M, and negative stockholders' equity of $85.9M. Offset by $2M Pfizer license revenue, R&D cost reduction, and advancing clinical milestones for two programs.

    Gap High · 39 → High · 27

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material

Thursday 12 Nov54 filings read · 54 material

  • 8-KFiled 12 Nov 2026Industrials

    Heartflow, Inc.HTFL

    8-K · Item 2.02 — Results of operations

    Heartflow reported Q3 2026 revenue of $72.9M (+57% YoY), beating expectations with 83.6% gross margin. Company raised full-year 2026 guidance to $262–264M (+49–50% growth) from prior $246–250M, citing accelerating U.S. revenue, expanding installed base, and strong Plaque Analysis adoption.

    Recognition: Strong 72 → Strong 68Gap Low · 5 → Medium · 13

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Transcontinental Realty Investors IncTCI

    8-K · Item 2.02 — Results of operations

    Q3 2026 net loss of $0.1M ($0.02/share) vs. prior-year net income of $0.7M ($0.08/share). Revenue up 8% but net operating loss doubled to $2.4M due to $1.4M increase in lease-up property expenses. Interest income declined $0.7M.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    QXO, Inc.QXO

    8-K · Item 2.02 — Results of operations

    Value: Balanced 62 → Strong 71

    The shares became cheaper on AIR's value read.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Crescent Biopharma, Inc.CBIO

    8-K · Item 2.02 — Results of operations

    Crescent Biopharma reported Q3 2026 results with significant clinical progress: completed dose escalation in Phase 1/2 ASCEND trial (125+ patients dosed), initiated CR-002 Phase 1/2 APOLLO trial, and achieved 9 IND clearances with partner Kelun-Biotech. Multiple data readouts expected in 2027.

    Recognition: Watch 33 → Watch 30Gap Very high · 77 → Very high · 83

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    Fermi Inc.FRMI

    8-K · Item 2.02 — Results of operations

    Fermi secured ~$200M upfront commitment from investment-grade hyperscaler for 600 MW at Project Matador, with additional $90M materials agreement pending. Demonstrates commercial traction and de-risks project funding.

    Gap Very high · 85 → Very high · 88

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Nektar TherapeuticsNKTR

    8-K · Item 2.02 — Results of operations

    Nektar advanced rezpegaldesleukin into Phase 3 development across atopic dermatitis and alopecia areata with all three ZENITH AD trials initiated and ZENITH AA on track for December start. Cash position strengthened to $952.9M from $245.8M year-end 2025.

    Gap Medium · 15 → High · 26

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    NeuroPace IncNPCE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $23.1M missed expectations with only 1% RNS growth. Full-year guidance slashed from $99.5–$101.5M to $91–$92M. CEO cited account-level disruptions and field organization changes. Net loss improved to $3.3M from $4.9M YoY, but trajectory remains concerning.

    Gap Low · 6 → Low · 0

    Attention caught up with the documented progress.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Semiconductors

    T1 Energy Inc.TE

    8-K · Item 2.02 — Results of operations

    T1 Energy signed 1.58GW new offtake contracts post-Section 232 proclamation, raised 2027 production guidance to 5.3GW (sold out), and advanced G2_Austin financing negotiations. Q3 net loss of $34.7M reflects intentional inventory build for 2027 deliveries.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Taysha Gene Therapies, Inc.TSHA

    8-K · Item 2.02 — Results of operations

    Taysha reports Q3 2026 results with strong TSHA-102 safety data (33 patients, no severe SAEs/DLTs), completed BLA-enabling manufacturing campaign meeting specifications, and expects pivotal trial interim data and FDA feedback in H1 2027.

    Gap Medium · 23 → High · 33

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Corteva, Inc.CTVA

    8-K · Item 2.02 — Results of operations

    Q3 2026 results show 9% organic sales decline and 17% EBITDA decline. Brazil market significantly weaker than anticipated due to farmer liquidity constraints and pricing pressure. Full-year guidance reduced; EBITDA now $1.1–1.125B (vs. prior guidance), EPS $0.76–$0.80.

    Recognition: Very strong 80 → Strong 73

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Industrials

    National Vision Holdings, Inc.EYE

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 4.8% to $510.5M with adjusted operating margin expanding 320 bps to 7.3%. Adjusted diluted EPS more than doubled to $0.30 from $0.13. Company accelerating new store openings one year ahead of plan.

    Recognition: Watch 37 → Watch 44Gap Medium · 10 → Medium · 22

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Immix Biopharma, Inc.IMMX

    8-K · Item 2.02 — Results of operations

    Immix reported 89% complete response rate in NEXICART-2 with potential 98% future rate. Strong cash position ($340.9M) extends runway to mid-2028. BLA submission planned mid-2027; NEXICART-3 initiation H1 2027. Key hires in technical operations and regulatory affairs.

    Recognition: Watch 42 → Watch 39Gap High · 33 → Very high · 45

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Absci CorpABSI

    8-K · Items 2.02, 8.01 — Results of operations

    Absci reported Q3 2026 results with ABS-201 HEADLINE trial on track for December interim proof-of-concept data in pattern hair loss. Announced Phase 2 endometriosis trial details (mid-2027 initiation) and appointed experienced Chief Commercial Officer. Cash runway extends to H2 2028.

    Recognition: Balanced 61 → Balanced 56Gap Medium · 18 → High · 37

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Accelerant HoldingsARX

    8-K · Item 2.02 — Results of operations

    Q3 2026: Exchange Written Premium grew 27% YoY to $1.33B; adjusted EBITDA $71.3M (25.4% margin); 26 new MGAs added. Pending Thoma Bravo acquisition expected to close H1 2027. GAAP net loss of $9.2M offset by adjusted net income of $38.2M.

    Recognition: Balanced 63 → Balanced 48

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Altimmune, Inc.ALT

    8-K · Item 2.02 — Results of operations

    Altimmune reports Q3 2026 results with $480M cash position. PERFORMA Phase 3 MASH trial progressing as planned; positive RECLAIM Phase 2 AUD data presented at AASLD. FDA End-of-Phase 2 meeting scheduled December 2026 for AUD program. RESTORE Phase 2 ALD enrollment complete.

    Gap High · 41 → Very high · 51

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    SpyGlass Pharma, Inc.SGP

    8-K · Items 2.02, 8.01 — Results of operations

    SpyGlass Pharma completed first implantations of BIM-DRS (next-generation drug delivery system), announced four-year efficacy data for lead BIM-IOL System (37% IOP reduction, 86% off drops), acquired IOL manufacturer AVS for $13M, and maintains $215.8M cash runway through 2028.

    Gap Medium · 21 → High · 41

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Kodiak Sciences Inc.KOD

    8-K · Item 2.02 — Results of operations

    Kodiak reported positive Phase 3 results for two lead programs (Zenkuda and tabirafusp-ted) in wet AMD, with Zenkuda meeting primary endpoint and 54% of patients achieving 6-month dosing. BLA submissions planned for Q4 2026 and Q2 2027. KSI-101 pivotal data expected December 2026.

    Gap Low · 5 → Medium · 12

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Suburban Propane Partners LpSPH

    8-K · Item 2.02 — Results of operations

    SPH reported FY2026 net income of $109.0M ($1.63/unit) and Adjusted EBITDA growth of 2.2% to $284.0M. Strong propane demand, RNG capacity expansion, debt reduction, and 7.7% distribution increase announced.

    Value: Strong 66 → Strong 69Gap Low · 7 → Medium · 22

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    DPC Holdings PLCDPC

    8-K · Item 2.02 — Results of operations

    Gap Very high · 58 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    EDGEWELL PERSONAL CARE CoEPC

    8-K · Item 2.02 — Results of operations

    EPC reported Q4 FY2026 organic sales growth of 3.1% and adjusted EPS of $0.78 (+50% YoY). Full-year adjusted EPS of $1.93 (+6.6% YoY) met guidance. FY2027 outlook projects organic sales growth of 1.0–3.0% and adjusted EPS of $1.85–$2.15.

    Gap Medium · 20 → High · 28

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Intellia Therapeutics, Inc.NTLA

    8-K · Item 2.02 — Results of operations

    Intellia hosted investor webcast on lonvo-z (CRISPR therapy for HAE). BLA accepted by FDA with priority review; PDUFA goal date March 10, 2027. Phase 3 HAELO trial achieved primary endpoint (62% attack-rate reduction) and key secondary endpoints with favorable safety. No advisory committee planned.

    Gap Very high · 64 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Arrowhead Pharmaceuticals, Inc.ARWR

    8-K · Item 2.02 — Results of operations

    ARWR reported FY2026 results with REDEMPLO commercial momentum (63% QoQ prescription growth, 950 cumulative prescriptions), FDA STAR program entry for plozasiran sHTG indication, successful Phase 3 data, and refinanced debt at lower rates with improved terms.

    Gap Very high · 82 → Very high · 86

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Industrials

    Enovix CorpENVX

    8-K · Item 2.02 — Results of operations

    Enovix reported Q3 2026 revenue of $11.0M (+38% YoY), record non-GAAP gross margin of 34.5%, and issued FY2027 guidance of $65–85M revenue (+75% to +128% YoY). Drone/defense pipeline grew 18% to $216M. Company restructured, retired $128M of 2030 Notes at 36% discount, and reduced annual costs by $8.5M.

    Gap High · 32 → High · 41

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026All industries

    Tetra Tech IncTTEK

    8-K · Items 2.02, 8.01 — Results of operations

    Tetra Tech reported record Q4 and FY2026 EPS, 13% YoY backlog growth to $4.67B, 90bps EBITDA margin expansion, and an 11% dividend increase—the 46th consecutive double-digit increase. Strong government contract wins totaling $1.9B support confidence in FY2027 guidance.

    Gap Low · 7 → High · 27

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    MeiraGTx Holdings plcMGTX

    8-K · Item 2.02 — Results of operations

    MeiraGTx reported Q3 2026 results with major regulatory milestones: MAA submission for bota-vec (XLRP) expected December 2026, BLA submission Q1 2027. Strong cash position ($184.7M) supports operations into H2 2028. Multiple clinical programs advancing; Lilly partnership generates revenue and milestone potential.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    United States Antimony CorpUAMY

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue up 16% YoY to $10.1M; gross profit surged 113% to $4.3M with margin expanding to 42%. Antimony pounds sold jumped 68% driven by DLA contract acceptance of 162k pounds. October DLA shipments added $3.6M revenue. Zeolite revenue grew 55% YoY.

    Gap Very high · 67 → Very high · 72

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    Anteris Technologies Global Corp.AVR

    8-K · Item 2.02 — Results of operations

    Anteris reported Q3 2026 progress on PARADIGM Trial enrollment across multiple countries, assumed occupancy of Minnesota manufacturing facility for production scaling, and appointed new CFO. Operating cash outflow was $22.9M.

    Gap Very high · 58 → Very high · 67

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    Tamboran Resources CorpTBN

    8-K · Item 2.02 — Results of operations

    Tamboran achieved first gas sales from Beetaloo Basin in September 2026, delivering 40 TJ/d to NT Government under fixed-price contract. Well performance confirms deliverability expectations with IP30 rates of 8.8–10.2 MMcf/d. Infrastructure completed on budget; ~US$180M pro forma cash balance.

    Recognition: Weak 22 → Weak 16

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Silence Therapeutics plcSLN

    8-K · Item 2.02 — Results of operations

    Silence Therapeutics announced acquisition by Merck KGaA (expected Q1 2027), reported positive Phase 2 SANRECO divesiran results with best-in-class dosing profile, and strengthened cash position to $247.7M via capital raise. Q3 operating losses improved significantly YoY.

    Gap Low · 0 → Low · 4

    Progress is running ahead of attention.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    TMC the metals Co Inc.TMC

    8-K · Item 2.02 — Results of operations

    NOAA delayed final certification decision to mid-December 2026 (from end-October) due to 1,600 public comments, with no identified application deficiencies. TMC and Allseas advancing capital-light phased production approach. U.S. government funding discussions ongoing for Brownsville processing facility.

    Gap Very high · 53 → Very high · 61

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    4D Molecular Therapeutics, Inc.FDMT

    8-K · Item 2.02 — Results of operations

    4DMT completed enrollment and randomization of 4FRONT-2 Phase 3 trial for 4D-150 in wet AMD; initiated 4SIGHT Phase 3 in DME; presented positive 2-year data; hired Chief Regulatory Officer. Topline data expected Q2 2027 and H2 2027.

    Gap Very high · 46 → Very high · 54

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Software / SaaS

    NIQ Global Intelligence plcNIQ

    8-K · Items 2.02, 8.01 — Results of operations

    NIQ exceeded guidance for 6th consecutive quarter with positive GAAP EPS ($0.12/share) for first time since IPO. Achieved 2.9x net leverage one quarter ahead of plan. Board authorized $150M share repurchase program.

    Recognition: Balanced 60 → Balanced 57Gap Low · 0 → Medium · 22

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 12 Nov 2026All industries

    Lithium Americas Corp.LAC

    8-K · Item 2.02 — Results of operations

    Lithium Americas raised Thacker Pass Phase 1 capex estimate from $2.93B to $3.83B (+31%), driven by labor inflation ($395M), tariffs/logistics ($100M), EPCM costs ($250M), and contingency increases. Requires ~$995M additional funding.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Assembly Biosciences, Inc.ASMB

    8-K · Item 2.02 — Results of operations

    Assembly Bio initiated Phase 2 study of ABI-6250 in chronic hepatitis delta virus, exercised 40% U.S. profit-share option for HSV program with Gilead, and received $75M collaboration extension fee, extending cash runway to 2029.

    Gap High · 29 → High · 39

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Anaptysbio, IncANAB

    8-K · Item 2.02 — Results of operations

    AnaptysBio reported Q1 FY2027 results with Jemperli achieving $1.0B in nine-month sales (29% YoY growth) and FDA approval in rectal cancer. Litigation with GSK/Tesaro post-trial hearing held; judgment expected Q4 2026/Q1 2027. Quimilza FDA decision due December 2026.

    Gap High · 28 → High · 39

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Semiconductors

    Diodes Inc /Del/DIOD

    8-K · Item 2.02 — Results of operations

    Diodes reported Q3 2026 record revenue of $532.6M (+36% YoY, +20% QoQ) with gross margin expanding 510 bps to 36.1%. Q4 guidance projects $550M revenue (+40% YoY) and 37% gross margin. Strong demand across automotive, industrial, and AI applications.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Relmada Therapeutics, Inc.RLMD

    8-K · Item 2.02 — Results of operations

    Relmada reports 18-month Phase 2 durability data for NDV-01 showing 86% complete response maintenance with no Grade ≥3 adverse events. IND submission on track for year-end 2026; Phase 3 SPECTRUM program renamed; $202.1M cash runway through 2029.

    Gap Medium · 17 → High · 31

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Prime Medicine, Inc.PRME

    8-K · Item 2.02 — Results of operations

    Prime Medicine dosed first patient in Phase 1/2 trial of PM577a (Wilson disease), received FDA IND clearance for PM647 (Alpha-1 Antitrypsin Deficiency), and raised $143.7M gross proceeds. BLA submission planned for PM359 in H1 2027. Cash runway extended through 2027.

    Recognition: Balanced 64 → Strong 68Gap Low · 3 → High · 29

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 12 Nov 2026Biotech

    CorMedix Inc.CRMD

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $54.5M beat consensus ($51.2M). Announced definitive agreement to acquire Heron Therapeutics assets (expected $125–150M annual revenue contribution in 2027, immediately accretive). FDA granted Priority Review for REZZAYO sNDA (PDUFA Q1 2027). Secured $150M term loan facility.

    News flow: Balanced 52 → Balanced 56Recognition: Balanced 46 → Watch 43Gap Very high · 48 → Very high · 87

    The filings read more positively.

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Kyverna Therapeutics, Inc.KYTX

    8-K · Item 2.02 — Results of operations

    Kyverna completed BLA submission for miv-cel in stiff person syndrome with priority review request. One-year data showed durable efficacy, disability reversal, and consistent safety. KYSA-6 gMG trial enrollment on-track for mid-2027 completion. Cash runway extends into 2028.

    Gap Very high · 59 → Very high · 68

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    Spectrum Brands Holdings, Inc.SPB

    8-K · Item 2.02 — Results of operations

    SPB reported FY2026 results with mixed signals: full-year adjusted EBITDA of $374.8M ahead of consensus (excluding $57.4M tariff refunds), but Q4 net sales declined 2.8% organically. FY2027 guidance is flat to low single-digit growth. Strategic Helen of Troy acquisition proposal rejected.

    Recognition: Strong 65 → Balanced 62Value: Weak 16 → Weak 24Gap Medium · 11 → Medium · 18

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Natural Gas Services Group IncNGS

    8-K · Item 2.02 — Results of operations

    NGS reported Q3 2026 results with record rental revenue and adjusted EBITDA. Company raised full-year guidance, increased dividend 60%, completed Flatrock integration successfully, and achieved 43,000 HP organic growth on track for 55,000 HP annual target.

    Gap Very high · 77 → Very high · 90

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Industrials

    EnerSysENS

    8-K · Items 2.02, 8.01 — Results of operations

    EnerSys reported Q2 FY2027 results with flat sales ($950M) but gross margin expansion to 29.9% (+80 bps), adjusted EPS of $3.22 (+22%), and announced definitive agreement to acquire Ultralife to expand defense power platform.

    Value: Balanced 55 → Balanced 58Gap Medium · 23 → High · 41

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Kardigan, Inc.KARD

    8-K · Item 2.02 — Results of operations

    Kardigan completed Phase 2b enrollment in danicamtiv KINSHIP-DCM trial with topline data expected Q2 2027; completed ataciguat KATALYST-AV Phase 2b enrollment with Week 48 data expected H2 2027. Cash position of $591.4M supports multiple data readouts and Phase 3 initiation through 2027.

    Gap Low · 0 → Medium · 21

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Candel Therapeutics, Inc.CADL

    8-K · Item 2.02 — Results of operations

    Candel reported Q3 2026 results with positive clinical data for aglatimagene across prostate cancer, NSCLC, and linoserpaturev in glioma. BLA submission planned mid-2027. Cash position of $203.1M funds operations into Q2 2028. Key hires strengthen commercial readiness.

    Recognition: Watch 43 → Watch 36Value: Balanced 57 → Watch 36Gap High · 42 → Very high · 56

    Market attention has faded.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026All industries

    Aebi Schmidt Holding AGAEBI

    8-K · Item 2.02 — Results of operations

    Q3 2026 showed revenue growth of 4.6% and net income improvement, but full-year guidance was reduced. Adjusted EBITDA guidance lowered from $175–195m to $170–180m; net sales guidance narrowed from $1.95–2.15b to $1.95–2.00b. Gross margin pressured by inflation; leverage guidance relaxed to <2.5x from 2.0x.

    Recognition: Watch 30 → Watch 25Gap High · 25 → Medium · 10

    Market attention has faded.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 12 Nov 2026Banks

    Jefferson Capital, Inc. / DEJCAP

    8-K · Item 2.02 — Results of operations

    Jefferson Capital reported Q3 2026 results with record collections (+35% YoY to $319.2M), record deployments (+111% to $318.0M), record ERC (+23% to $3.6B), and record revenue (+23% to $185.5M). Net income of $46.9M and EPS of $0.76 delivered.

    Gap Very high · 56 → Very high · 64

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Erasca, Inc.ERAS

    8-K · Item 2.02 — Results of operations

    Erasca announced FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic cancer, strengthened cash position to $948M via upsized financing, appointed experienced R&D leadership, and advanced toward three registration-enabling trials in pancreatic and lung cancers.

    Gap Medium · 15 → Medium · 22

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Biotech

    SELLAS Life Sciences Group, Inc.SLS

    8-K · Item 2.02 — Results of operations

    SELLAS announced Q3 2026 results with $134.7M cash, Phase 3 REGAL trial 80th event triggering topline results expected this month, Phase 2 SLS009 enrollment at 40/80 patients with Q4 data expected, and favorable Phase 2 relapsed/refractory AML data (54-57% ORR).

    Recognition: Watch 39 → Watch 32Gap High · 28 → Very high · 45

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Monopar TherapeuticsMNPR

    8-K · Item 2.02 — Results of operations

    Monopar presented Phase 3 baseline data for ALXN1840 in Wilson disease showing significant disease burden in treatment-experienced patients. Company initiated rolling NDA submission to FDA and hired experienced medical affairs executive. Cash position of $129.4M supports operations through March 2028.

    Gap Low · 3 → Medium · 16

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 12 Nov 2026Biotech

    Twist Bioscience CorpTWST

    8-K · Item 2.02 — Results of operations

    Twist Bioscience reported FY2026 record revenue of $459.4M (+22% YoY), gross margin expansion to 52.4%, and positive adjusted EBITDA in Q4. FY2027 guidance of $550–560M revenue (+21% midpoint) with expected positive adjusted EBITDA.

    Recognition: Strong 79 → Strong 76Value: Watch 37 → Watch 43Gap Medium · 19 → High · 27

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026All industries

    Aveanna Healthcare Holdings, Inc.AVAH

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 11.8% YoY to $695.5M; net income surged to $45.5M from $14.1M; Adjusted EBITDA increased 25.0% to $100.1M. Full-year 2026 revenue and Adjusted EBITDA guidance raised.

    Recognition: Balanced 57 → Balanced 54Value: Weak 16 → Weak 20Gap Medium · 18 → High · 30

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 12 Nov 2026Industrials

    YETI Holdings, Inc.YETI

    8-K · Item 2.02 — Results of operations

    YETI reported Q3 2026 adjusted sales growth of 6% and adjusted EPS growth of 49%, but reduced full-year 2026 outlook. Adjusted sales growth guidance lowered from 7-8% to ~6%; adjusted EPS guidance narrowed from $2.94-$3.00 to $2.90-$2.95. Management cited cautious consumer environment and uneven demand.

    Recognition: Balanced 52 → Balanced 45Value: Balanced 55 → Strong 69Gap Low · 4 → Low · 0

    Market attention has faded.

    The shares became cheaper on AIR's value read.

    The gap closed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material

Tuesday 10 Nov40 filings read · 40 material

  • 8-KFiled 10 Nov 2026Industrials

    Janus International Group, Inc.JBI

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue declined 2.8% YoY to $213.1M; net loss of $13.3M vs. prior-year profit; Adjusted EBITDA fell 22% to $34M. Full-year 2026 guidance reduced significantly, with Adjusted EBITDA now $127–133M (down 22.7% at midpoint). Goodwill impairment of $18.3M recorded.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Software / SaaS

    D-Wave Quantum Inc.QBTS

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue up 21% YoY to $4.5M; YTD bookings surged 611% to $37.4M. RPO jumped 1,221% to $38.3M. Secured $100M CHIPS Act funding. Announced major partnerships with NTT DOCOMO, CGI, LG CNS; deployed systems in Italy.

    Gap High · 31 → High · 40

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Liquidia CorpLQDA

    8-K · Items 2.02, 8.01 — Results of operations

    YUTREPIA Q3 2026 net sales reached $222.7M (31% QoQ growth). Company resolved all litigation with United Therapeutics via $380.7M settlement, securing uninterrupted patient access. Fifth consecutive quarter of positive adjusted EBITDA ($140.5M). Fast Track designation granted for SSc-RP indication.

    No notable change in AIR's read.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Mercury Systems IncMRCY

    8-K · Items 2.02, 5.02 — Results of operations

    Mercury Systems reported record Q1 FY27 bookings ($370M, +48% YoY), revenue ($253M, +12.4% YoY), adjusted EBITDA ($56M, +58.6% YoY), and backlog ($2.1B, +44.7% YoY). Company raised FY27 outlook based on solid execution.

    Value: Watch 25 → Weak 20Gap Low · 0 → High · 36

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Veradermics, IncMANE

    8-K · Item 2.02 — Results of operations

    Veradermics reported positive Phase 3 and Phase 2/3 trial results for VDPHL01 in male and female pattern hair loss, with robust hair growth, favorable safety profiles, and strong cash position of $798.4M funding operations into 2030.

    Gap High · 42 → Very high · 57

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 10 Nov 2026All industries

    Anterix Inc.ATEX

    8-K · Item 2.02 — Results of operations

    Anterix reported Q2 FY2027 net loss of $4.993M vs. prior-year net income of $53.536M. Spectrum revenue grew modestly to $1.958M, but operating losses and negative cash flow from operations signal execution challenges despite $107.5M cash balance and spectrum licensing progress.

    Gap Low · 4 → Low · 0

    The gap closed as the filings read less positively.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Tyra Biosciences, Inc.TYRA

    8-K · Item 2.02 — Results of operations

    Tyra reported Phase 2 SURF302 results showing 79% ORR and 64% CR rate for dabogratinib in IR NMIBC, completed $400M financing providing runway through 2030, and advanced three Phase 2 programs across oncology and rare disease indications.

    Gap Medium · 14 → High · 28

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Alto Neuroscience, Inc.ANRO

    8-K · Item 2.02 — Results of operations

    Alto Neuroscience reported Q3 2026 results with $319.8M cash position (up from $177M), enabling operations through 2030. PACE-1 trial on track for 2H 2027 data; Phase 3 expansion approved. $100M financing completed in July 2026.

    Recognition: Balanced 53 → Balanced 57

    More of the market is starting to notice.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Achieve Life Sciences, Inc.ACHV

    8-K · Item 2.02 — Results of operations

    AchieveRx reported positive 52-week ORCA-OL trial data showing quit rates rising to 31.2% by end of treatment in hard-to-treat smokers. NDA resubmission on track for Q4 2026 with potential FDA approval by Q2 2027. Strong cash position of $201.5M supports launch readiness.

    Gap Low · 0 → Medium · 14

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Hyliion Holdings Corp.HYLN

    8-K · Item 2.02 — Results of operations

    Hyliion reported Q3 2026 revenue of $7.5M (vs. $0.8M prior year), raised full-year guidance to ~$18M from $15M, and announced ~$50M in total new military awards for 2026. Delivered KARNO units to Navy and first commercial customer; $45.5M in remaining authorized military contract funding provides revenue visibility.

    Recognition: Watch 36 → Watch 28Gap Low · 1 → Medium · 19

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Capricor Therapeutics, Inc.CAPR

    8-K · Item 2.02 — Results of operations

    Capricor announced Q3 2026 results with Deramiocel BLA under FDA review (PDUFA Nov 22). Two-year HOPE-3 open-label extension data showed 76% slowing of upper limb decline; cardiac results won AHA award. Cash position $198.5M; manufacturing facility operational.

    Gap High · 25 → High · 36

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Semiconductors

    Kopin CorpKOPN

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 52% YoY to $18.2M; operating loss narrowed to $0.5M sequentially. Additional $18.6M U.S. Army IBAS award (total $34M) and Neural I/O on track for CES 2027 demonstration. New $2.4M OLED order received.

    Gap Very high · 73 → Very high · 78

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Amprius Technologies, Inc.AMPX

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $39.1M (+83% YoY), net loss improved to $3.5M. Company raised 2026 revenue outlook to $145M and secured $75M U.S. Department of War contract for NDAA-compliant cell production.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Gossamer Bio, Inc.GOSS

    8-K · Item 2.02 — Results of operations

    Gossamer submitted first NDA for seralutinib in PAH to FDA in September 2026. Secured $25M upfront with up to $125M additional capital upon FDA acceptance. Reacquired worldwide rights from Chiesi. Cash position $51.2M as of Q3 2026.

    Recognition: Weak 24 → Watch 38Gap Medium · 11 → Medium · 21

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026All industries

    Alliance Laundry Holdings Inc.ALH

    8-K · Item 2.02 — Results of operations

    Q3 2026 net revenues $461M (+5% YoY), net income $65M, Adjusted EBITDA $127M (+14% YoY, 27.5% margin). Full-year Adjusted EBITDA guidance raised to ~10% growth (high end of prior 8-10% range). Net Leverage improved to 2.25x; $45M debt repaid, $75M stock repurchased.

    Gap High · 28 → High · 42

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Astronics CorpATRO

    8-K · Item 2.02 — Results of operations

    Astronics reported record Q3 2026 sales of $271.7M (+28.5% YoY) and record operating income of $54.0M (19.9% margin). Aerospace segment achieved 23.4% operating margin with record backlog of $670M. Company maintains full-year 2026 guidance of $1.02–$1.04B revenue.

    Value: Watch 36 → Watch 31Gap Medium · 17 → High · 29

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Software / SaaS

    Rigetti Computing, Inc.RGTI

    8-K · Item 2.02 — Results of operations

    Rigetti achieved 99.5% median two-qubit fidelity on 108-qubit system, validating chiplet architecture. Signed $100M definitive agreement with U.S. Department of Commerce under CHIPS Act. Nine-month 2026 revenue grew 110% YoY to $10.9M; full-year guidance ~$20M.

    Gap Very high · 67 → Very high · 71

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Kura Oncology, Inc.KURA

    8-K · Item 2.02 — Results of operations

    KOMZIFTI delivered 53% sequential revenue growth to $13.9M with 30% increase in new patient starts and maintained majority market share. FDA alignment achieved for darlifarnib registrational study. Strong cash position of $492.1M plus $300M financing capacity secured.

    Gap Low · 5 → Medium · 16

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Sonos IncSONO

    8-K · Item 2.02 — Results of operations

    Sonos returned to revenue growth in FY2026 with 7% YoY increase to $1.547B, delivered 39% Adjusted EBITDA growth to $184M, and beat Q4 guidance. Board authorized new $150M share repurchase program.

    Recognition: Balanced 61 → Strong 66Value: Watch 30 → Watch 26Gap Low · 0 → Low · 9

    More of the market is starting to notice.

    The shares became dearer on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026All industries

    Sally Beauty Holdings, Inc.SBH

    8-K · Item 2.02 — Results of operations

    Sally Beauty reported Q4 FY2026 results with 0.6% net sales growth, 22% GAAP diluted EPS growth, and 13% adjusted diluted EPS growth. Full-year adjusted EPS grew 9%. FY2027 guidance provided with comparable sales growth of 1-2% and adjusted operating earnings of $334-347M.

    Gap Low · 3 → Medium · 15

    Progress is running ahead of attention.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Arbutus Biopharma CorpABUS

    8-K · Item 2.02 — Results of operations

    Arbutus reported Q3 2026 results with $337.5M cash position, $230M shareholder capital return, expanded LNP patent litigation against Pfizer/BioNTech, and FDA clinical hold lift on AB-101 oral PD-L1 inhibitor.

    Gap High · 44 → Very high · 48

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Prime Medicine, Inc.PRME

    8-K · Items 2.02, 8.01 — Results of operations

    Prime Medicine disclosed preliminary Q3 2026 cash position of $61.2M (excluding $13.7M restricted cash) and posted updated corporate presentation. Unaudited estimates subject to completion of financial close; final results pending in 10-Q filing.

    Recognition: Strong 69 → Balanced 64

    Market attention has faded.

    The price trend weakened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026All industries

    Gevo, Inc.GEVO

    8-K · Item 2.02 — Results of operations

    Gevo reported record Q3 2026 results: $83M revenue (93% YoY growth), $23M net income vs. $8M loss YoY, $44M Adjusted EBITDA. Raised FY2026 guidance to >$90M and FY2027 to >$70M Adjusted EBITDA. Carbon business performing strongly.

    Recognition: Watch 40 → Balanced 49Value: Balanced 50 → Balanced 53Gap Very high · 49 → Very high · 52

    More of the market is starting to notice.

    The shares became cheaper on AIR's value read.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Olema Pharmaceuticals, Inc.OLMA

    8-K · Item 2.02 — Results of operations

    Olema reports Q3 2026 results with $413.8M cash, strong enrollment in Phase 3 trials, and on-track top-line data from pivotal OPERA-01 trial expected Q1 2027. CFO appointment signals commercialization preparation.

    Gap Low · 4 → Medium · 20

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Biotech

    Cullinan Therapeutics, Inc.CGEM

    8-K · Item 2.02 — Results of operations

    Cullinan reported Q3 2026 results with multiple clinical catalysts: CLN-978 multi-dose data in three autoimmune indications coming December; velinotamig initiated global Phase 1/2 study; CLN-049 potentially registrational Phase 2 in R/R AML underway; zipalertinib NDA submission initiated under FDA Real-Time Review. Cash position $313.8M provides runway into 2029.

    Recognition: Balanced 49 → Balanced 45Gap High · 27 → Very high · 47

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Firefly Aerospace Inc.FLY

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $110.7M (up 259% YoY), record $1.7B backlog, cleanroom expansion completed, first European launch contracts signed, $94M Space Force contract awarded, and $1.3B AST SpaceMobile deal announced.

    Gap Very high · 55 → Very high · 66

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026All industries

    BrightView Holdings, Inc.BV

    8-K · Item 2.02 — Results of operations

    BrightView reported FY2026 revenue growth of 1.5% but Adjusted EBITDA declined 6.6% YoY. Development Services fell 9.4%. However, Land Maintenance showed three consecutive quarters of growth (3.3% Q4), and FY2027 guidance projects 3-4% Land Maintenance growth with margin expansion.

    Fundamentals: Watch 31 → Watch 27Value: Balanced 52 → Balanced 55Gap Very high · 59 → Very high · 48

    The reported numbers weakened.

    The shares became cheaper on AIR's value read.

    The gap narrowed as the filings read less positively.

    The price trend weakened.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026All industries

    Resideo Technologies, Inc.REZI

    8-K · Item 2.02 — Results of operations

    Recognition: Balanced 48 → Balanced 54Value: Balanced 60 → Balanced 45Gap Very high · 84 → Very high · 78

    The shares became dearer on AIR's value read.

    The gap narrowed — attention is catching up.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026Semiconductors

    Ambiq Micro, Inc.AMBQ

    8-K · Item 2.02 — Results of operations

    Q3 2026 net sales surged 110% YoY to $38.1M; gross profit doubled, outpacing revenue growth with 440bps margin expansion. Active customer base grew 50% YoY with seven $1M+ customers. Q4 guidance of $43.5–$44.5M reflects accelerating edge AI demand.

    Recognition: Watch 38 → Watch 33Gap Low · 5 → Medium · 23

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026All industries

    Evolv Technologies Holdings, Inc.EVLV

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue grew 10% YoY to $47.3M; ARR accelerated 20% YoY to $140.5M. Net loss widened to $(15.6)M, but Adjusted EBITDA of $4.7M and cash position of $66.9M remain solid. FY2026 guidance maintained at 25-27% growth.

    Gap Low · 3 → Medium · 21

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Energy Vault Holdings, Inc.NRGV

    8-K · Item 2.02 — Results of operations

    Energy Vault reported Q3 2026 revenue of $13.1M in line with expectations, achieved $2.3B backlog (147% YoY growth), raised FY2026 guidance to top half of range ($290–310M), and provided 2027 guidance ($600–700M revenue, $40–50M adjusted EBITDA). Cash tripled YoY to $236M.

    Gap Very high · 85 → Very high · 88

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Watch
    Material
  • 8-KFiled 10 Nov 2026All industries

    Angel Studios, Inc.ANGX

    8-K · Item 2.02 — Results of operations

    Angel Studios reported Q3 2026 revenue of $159.0M (+107.7% YoY), Guild membership grew to 2.94M (+1.36M YoY), net loss narrowed to $5.2M from $38.5M YoY, and Adjusted EBITDA loss improved significantly. Positive operating cash flow of $10.3M in Q3.

    Recognition: Balanced 49 → Balanced 53Gap High · 40 → Very high · 47

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    More facts
    Momentum: Balanced
    Material
  • 8-KFiled 10 Nov 2026All industries

    American Integrity Insurance Group, Inc.AII

    8-K · Item 2.02 — Results of operations

    Q3 2026 earnings significantly exceeded prior year with 115% net income growth to $28.4M, 83% revenue growth, 57% YoY voluntary new business policy growth (41K policies), and improved combined ratio of 70.6% vs 78.9% YoY.

    News flow: first measured — Balanced 51Recognition: Watch 44 → Balanced 47Gap first measured: Medium · 13

    AIR measured this for the first time; no change to report.

    More of the market is starting to notice.

    More facts
    Momentum: Very strong
    Material
  • 8-KFiled 10 Nov 2026All industries

    Grocery Outlet Holding Corp.GO

    8-K · Item 2.02 — Results of operations

    Q3 2026 showed modest sales growth (0.9%) with positive comp sales (0.5%), but YTD results included $158M goodwill impairment. Adjusted EPS declined 24% YTD. Guidance lowered for adjusted EBITDA and net store openings.

    No notable change in AIR's read.

    More facts
    Momentum: Strong
    Material
  • 8-KFiled 10 Nov 2026Industrials

    Nextnav Inc.NN

    8-K · Item 2.02 — Results of operations

    NextNav reported Q3 2026 results with regulatory progress, technical milestones, and new partnerships. Strong balance sheet: $290.9M cash/investments, zero debt. Revenue grew YoY but company remains unprofitable with $48.6M nine-month net loss.

    Recognition: Watch 43 → Watch 40Gap Low · 6 → Medium · 20

    Market attention has faded.

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026Semiconductors

    Lightpath Technologies IncLPTH

    8-K · Item 2.02 — Results of operations

    LightPath reported Q1 FY2027 revenue of $20.8M (+38% YoY), gross margin expansion to 41.4%, and record backlog of $132.9M (+54% YoY). Net loss improved to $1.7M from $2.9M. Secured $30M+ in C-UAS orders and 50,000+ optical assemblies for drone systems.

    Gap Very high · 54 → Very high · 69

    Progress is running ahead of attention.

    More facts
    Momentum: Weak
    Material
  • 8-KFiled 10 Nov 2026All industries

    GLADSTONE LAND CorpLAND

    8-K · Item 2.02 — Results of operations

    Gladstone Land reported Q3 2026 net income of $11.0M vs. $2.1M YoY, driven by strong pistachio and almond pricing (67% and 18-25% increases respectively), $16.8M participation rent revenue, and $2.9M crop profit. AFFO surged to $0.35/share from $0.04/share. Offset by $2.2M impairment charge and lower 2026 pistachio yields from March heat event.

    Gap Low · 0 → Medium · 15

    Progress is running ahead of attention.

    More facts
    Momentum: Watch
    Material

Monday 9 Nov86 filings read · 86 material

  • 8-KFiled 9 Nov 2026All industries

    EquipmentShare.com IncEQPT

    8-K · Item 2.02 — Results of operations

    EquipmentShare reported Q3 2026 results with 55% total revenue growth to $1.47B, 49% rental segment growth, net income of $20M (vs. $6M YoY), and rental EBITDA margin expansion to 44%. Management raised full-year outlook confidence.

    No notable change in AIR's read.

    More facts
    Momentum: Weak
    Material

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.